Home › Research › Treatments
From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation
Christina V. Frost, Martin Zacharias. Proteins: Structure, Function, and Bioinformatics, 2020-08-03
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
Alzheimer's disease is one of the most common causes of dementia. It is believed that the aggregation of short A β ‐peptides to form oligomeric and protofibrillar amyloid assemblies plays a central role for disease‐relevant neurotoxicity. In recent years, passive immunotherapy has been introduced as a potential treatment strategy with anti‐amyloid antibodies binding to A β ‐amyloids and inducing their subsequent degradation by the immune system. Although so far mostly unsuccessful in clinical studies, the high‐dosed application of the monoclonal antibody Aducanumab has shown therapeutic potential that might be attributed to its much greater affinity to A β ‐aggregates vs monomeric A β ‐peptides. In order to better understand how Aducanumab interacts with aggregated A β ‐forms compared to monomers, we have generated structural model complexes based on the known structure of Aducanumab in complex with an A β 2 − 7 ‐eptitope. Structural models of Aducanumab bound to full‐sequence A β 1 − 40 ‐monomers, oligomers, protofilaments and mature fibrils were generated and investigated using extensive molecular dynamics simulations to characterize the flexibility and possible additional interactions. Indeed, an aggregate‐specific N‐terminal binding motif was found in case of Aducanumab binding to oligomers, protofilaments and fibrils that is located next to but not overlapping with the epitope binding site found in the crystal structure with A β 2 − 7 . Analysis of binding energetics indicates that this motif binds weaker than the epitope but likely contributes to Aducanumab's preference for aggregated A β ‐species. The predicted aggregate‐specific binding motif could potentially serve as a basis to reengineer Aducanumab for further enhanced preference to bind A β ‐aggregates vs monomers.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Frost, C. V., & Zacharias, M. (2020). From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.25978
Vancouver
Frost CV, Zacharias M. From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. Proteins: Structure, Function, and Bioinformatics. 2020. doi:10.1002/prot.25978.
BibTeX
@article{frost2020-87e1c4ad,
author = {Frost, Christina V. and Zacharias, Martin},
title = {{From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation}},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2020},
doi = {10.1002/prot.25978},
url = {https://doi.org/10.1002/prot.25978}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In order to better understand how Aducanumab interacts with aggregated A β ‐forms compared to monomers, we have generated structural model complexes based on the known structure of Aducanumab in complex with an A β 2 − 7 ‐eptitope.
- Analysis of binding energetics indicates that this motif binds weaker than the epitope but likely contributes to Aducanumab's preference for aggregated A β ‐species.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 21 of the 56 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Proteins: Structure, Function, and Bioinformatics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 21 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 56 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “presenilin”
343 studies in the library carry the topic tag “presenilin”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 343 tagged studies.